Transcode Therapeutics

TransCode Therapeutics is an emerging RNA oncology company founded on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapies. The company has developed a platform of therapeutic candidates aimed at targeting various tumor types with the goal of significantly improving patient outcomes. The company’s lead therapeutic candidate, TTX-MC138, focuses on treating metastatic cancer, which accounts for approximately 90% of all cancer deaths, resulting in over 9 million global deaths annually. The company believes TTX-MC138 has the potential to induce regression across a range of cancers without recurrence, including breast, pancreatic, ovarian, and colorectal cancers, as well as glioblastoma. The company’s other candidates, TTX-siPDL1 and TTX-siLIN28b, focus on treating tumors by targeting PD-L1 and Lin28b, respectively.